BERNSTEIN Barry M.,DUTTA Sandeep,LIU Wei,PODSADECKI Thomas J.,CAMPBELL Andrew L.,MENON Rajeev M.,LIN Chih-Wei,WANG Tianli,AWNI Walid M.,MENSING Sven,LIN Ch
申请号：
SI201430265
公开号：
SI2968301T1
申请日:
2014.03.14
申请国别(地区):
SI
年份:
2017
代理人:
摘要：
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
